Astellas Pharma Inc.
4503・Prime Market・Pharmaceuticals
Governance
As a company with an Audit and Supervisory Committee, the Board of Directors consists of 12 members, 8 of whom are independent outside directors (a majority). A Nomination Committee and a Compensation Committee have been established, each chaired by an independent outside director. An annual Board effectiveness evaluation is conducted by an external organization, with the effectiveness score rated at 4.5 out of a possible 5 points.
Risk Management
Risks are categorized into business opportunity risks and business execution risks, with global and divisional "Risk & Resilience Committees" established. In addition to forming a crisis response team for geopolitical risks (the situations in Ukraine and the Middle East), the company conducts cyber crisis management exercises, building a multi-layered risk management framework.
Shareholder Returns
The company's policy is to prioritize growth investment while aiming for stable and sustainable dividend increases based on mid- to long-term profit growth. For FY2025 (ending March 2026), the annual dividend is ¥78 per share (interim ¥39, year-end ¥39), with total dividends of ¥141,116 million and a payout ratio of 47.9%. For the next fiscal year (FY2027, ending March 2027), the dividend is forecast at ¥80 per share. Share buybacks are also conducted flexibly to improve capital efficiency.
Dividend Policy
The company strives for stable and sustainable dividend increases based on mid- to long-term consolidated profit growth, paying dividends twice a year (interim and year-end). For FY2025 (ending March 2026), the actual dividend was ¥78 per share (interim ¥39 + year-end ¥39), with total dividends of ¥141,116 million and a payout ratio of 47.9%. For the next fiscal year (FY2027, ending March 2027), the forecast dividend is ¥80 per share (interim ¥40 + year-end ¥40), with a payout ratio forecast of 47.8%. Share buybacks are conducted flexibly as needed to improve capital efficiency and increase earnings per share.
ESG
In response to climate change, the company has expressed support for the TCFD recommendations and has set targets of a 63% reduction in Scope 1+2 emissions by FY2030 (base year FY2015) and a 37.5% reduction in Scope 3 emissions. In terms of human capital, the company promotes psychological safety, diversity, and organizational flattening, achieving global diversity such that 72% of employees at manager level and above are non-Japanese.
Last updated: June 16, 2026